%0 Case Reports
%T [A case of immune-related gastroesophagitis with laryngopharyngitis caused by immune checkpoint inhibitors in nonsmall cell lung cancer].
%A Oka Y
%A Hamano Y
%A Nakamura R
%A Mabuchi K
%A Ochi M
%A Yamaguchi Y
%A Okawara H
%A Okawara A
%A Kakinoki N
%A Kamoshida T
%J Nihon Shokakibyo Gakkai Zasshi
%V 121
%N 3
%D 2024
%M 38462470
暂无%R 10.11405/nisshoshi.121.221
%X With the advent of immune checkpoint inhibitors (ICI), cancer treatment options have widened in recent years. However, ICI-specific adverse events (irAEs) have been reported. Lower gastrointestinal lesions, such as colitis and enteritis, account for most gastrointestinal irAEs, and reports of upper gastrointestinal lesions are rare. We report a rare case of gastroesophagitis associated with ICI. The patient was a 64-year-old male. He was diagnosed with lung adenocarcinoma stage IIIB (cT2aN3M0), and pembrolizumab (PEM) was started as a first-line treatment. Severe gastroesophagitis with laryngopharyngitis was confirmed 5 months after PEM administration. These improved after withdrawal of PEM and steroid administration. Reports of ICI-associated gastritis remain limited, especially with laryngopharyngitis;therefore, we consider this case as valuable, in which we confirmed the clinical features of ICI-associated gastroesophagitis and its therapeutic effects.